Crystal Loos noticed that her young daughter began acting differently in the spring of 2023. By July 2024, her once bubbly ...

Key challenges include logistical hurdles, such as the need for specialized training and infrastructure, and financial ...

Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...

Miv-cel was well-tolerated, with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) observed. Grade 3/4 neutropenia, a known adverse event ...

Could a single night change the life of a very enthusiastic and very happy little child beyond recognition? This is what an ...

Background A 46-year-old woman presented to a local hospital with acute respiratory failure and a 2-year progressive history of fatigue, personality changes, increased sweating, dysphagia with ...

Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 Miv-cel ...

It has been about a month since the last earnings report for Adma Biologics (ADMA). Shares have added about 43.3% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

The disorders hit children suddenly and with frightening symptoms — hallucinations, tics, aggression, severe anxiety and restrictive eating. It is, many parents of sufferers say, like someone has ...

Modifying existing phototherapy procedures, introducing adjunct therapies and changing light sources may improve HDFN ...

Correspondence to Professor Bruce V Taylor, Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia; bruce.taylor{at}utas.edu.au Despite 30 years of research there ...

Doctors explain the early warning signs of Guillain-Barre syndrome, who is at risk, and why early hospital care and timely ...